Clinical Trial Update: Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease [Phase 3]

View source ↗

Summary

This entry reports the long-term extension results of the RECOVER study evaluating 24-hour transdermal rotigotine in idiopathic Parkinson's disease. The Phase 3…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Rotigotine transdermal patch (rotigotine)

Snippet

Sponsor: UCB Pharma | Conditions: Parkinson's Disease | Phase 3 | Status: TERMINATED | Results posted: 2010-04-02